Skip to main content

Featured

TSX Hits Record High as Iran Deal Lifts Markets — Daily Update, June 16, 2026

Oil tumbles on Strait of Hormuz reopening framework. All eyes on the Federal Reserve as Kevin Warsh chairs his first policy meeting. Here is everything moving Canadian wallets today. Tuesday, June 16, 2026  |  MoneySavings.ca 🇨🇦 TSX — Another Record on the Books The S&P/TSX Composite closed at a fresh all-time high on Monday, June 15, topping 35,398 intraday before finishing near the upper end of its range. The index is now up more than 11% year-to-date , the second-best performance among major global indexes tracked through mid-June — behind only Japan's Nikkei (+31%). Monday's rally was broad-based, fuelled by a surge in risk appetite following the announcement of a U.S.–Iran peace framework over the weekend. Energy, financials, and materials all participated, though energy stocks gained somewhat less than the others as crude oil prices simultaneously fell sharply on the Strait of Hormuz reopening news — a rare case where the same headline pushed the index up and one ...
Post a Comment
Read more

article

Labels

New Hope for Alzheimer’s Patients: Health Canada Approves First Disease-Modifying Treatment


Health Canada has granted conditional approval for LEQEMBI® (lecanemab), a groundbreaking therapy shown to slow the progression of early Alzheimer’s disease. Developed by Eisai Co., Ltd. and Biogen Inc., the drug is the first in Canada to directly target one of the underlying causes of the disease by reducing amyloid-beta aggregates in the brain.

LEQEMBI is authorized for adults diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease, specifically for patients who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology.

The approval follows results from the global Clarity AD Phase 3 trial, which demonstrated that lecanemab significantly slowed cognitive and functional decline compared to placebo. This milestone offers new hope to the more than 771,000 Canadians currently living with dementia, a number projected to rise to 1 million by 2030.

While the approval comes with conditions requiring further data, experts say this marks a pivotal step in shifting Alzheimer’s treatment from symptom management to disease modification.


Labels:

Comments

Post a Comment